Document is current
Any future updates will be listed below
-
Authors
Matikas, Alexios https://orcid.org/0000-0002-4122-9624
Tzoras, Evangelos
Sarafidis, Michail
Sifakis, Emmanouil G. https://orcid.org/0000-0001-9919-4471
Bjöhle, Judith
Barnekow, Elin
Margolin, Sara
Isaksson-Friman, Erika
Kessler, Luisa Edman
Zouzos, Athanasios https://orcid.org/0000-0003-2654-827X
Johansson, Hemming
Hellström, Mats
Agartz, Susanne
Grybäck, Per https://orcid.org/0000-0002-1141-6234
Salgkamis, Dimitrios https://orcid.org/0000-0002-3020-0359
Zerdes, Ioannis https://orcid.org/0000-0002-8304-2462
Wang, Kang https://orcid.org/0000-0001-5401-1803
Hartman, Johan https://orcid.org/0000-0002-6500-8527
Acs, Balazs https://orcid.org/0000-0002-0972-4633
Sun, Wenwen
Boyaci, Ceren
Villacampa, Guillermo
Pascual, Tomas https://orcid.org/0000-0001-8431-3183
Gavila, Joaquin
Prat, Aleix https://orcid.org/0000-0003-2377-540X
Perou, Charles
Brandberg, Yvonne
Bergh, Jonas https://orcid.org/0000-0001-5526-1847
Hatschek, Thomas
Foukakis, Theodoros https://orcid.org/0000-0001-8952-9987
-
Funding
Funding for this research was provided by:
Cancerfonden
Radiumhemmets Forskningsfonder
Vetenskapsrådet
Pfizer
- License Information
-
More Information
Article History
Received: 29 August 2025
Accepted: 13 March 2026
First Online: 8 April 2026
Competing interests
: A.M.: speaker (no personal fees): Roche, Seagen; consultant (no personal or institutional fees): Roche, AstraZeneca, Veracyte; research funding paid to institution by Merck, AstraZeneca, Novartis, Veracyte; advisory board: Nordic Pharma (no personal or institutional fees). I.Z.: institutional research grants from Gilead and honoraria paid to his institution from Novartis. J.H.: Leadership and ownership interests in Stratipath AB. Speaker: Gilead. Honoraria from MSD, Pfizer, Lilly. Research funding (paid to institution): Novartis, Cepheid. G.V.: speaker’s fee from Pfizer, MSD, GSK and Pierre Fabre; advisory role with AstraZeneca; consultant fees from Reveal Genomics. T.P.: speaker’s fee from Pfizer, AstraZeneca, Novartis, Veracyte and Argenetics; advisory role with Novartis. J.B.: research funding to institution (Karolinska Institutet and/or Karolinska University Hospital) from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi; honoraria from UpToDate paid to Asklepios Medicin HB; head of advisory board at Stratipath AB; Coronis and Asklepios Cancer Research AB hold shares of Stratipath AB; honoraria for lectures/educational conferences for postgraduates courses from AstraZeneca paid to Coronis and Asklepios Cancer Research AB, chairmanship for meetings arranged by Akademikonferens on behalf of Roche, and a lecture for Novartis, honoraria to Coronis and Asklepios Cancer Research AB for both activities. T.F.: institutional fees for consultancy to AstraZeneca, Gilead and Roche; personal fees for consultancy to Affibody, Pfizer, Novartis, Veracyte, Exact Sciences; honoraria from UpToDate; research funding to institution from Pfizer, AstraZeneca, Novartis and Veracyte. All the other authors had no potential conflicts of interest to disclose.
